Abstract selected for a poster at the AACR
2 février 2026
The annual meeting of the American Association for Cancer Research (AACR) will be held in April in San Diego. An abstract presenting the work conducted on the mechanisms of action, anticancer effects, and toxicity of HEPHA-440 has been selected for poster presentation and will be presented by Laury-Anne Leroy.
Start of the toxicology study
28 janvier 2026
At C.RIS Pharma, the first dose of HEPHA-440 was administered intravenously to three rabbits, with no signs of toxicity observed. Dose escalation is ongoing.
Project presentation during a Lyonbiopole event
14 octobre 2025
The RHU SyStInn project was presented during the “Innovation Pitches” session of the 20th collaborative day organized by Lyonbiopole by Juliette Humeau, in front of an audience composed of industry representatives, academics, and clinicians.
Selection of C.RIS Pharma for the regulatory toxicology study
September 10, 2025
After reviewing the proposals received, C.RIS Pharma, a Contract Research Organisation (CRO) located in Saint-Malo, was awarded the contract to conduct the preclinical regulatory toxicology study described below. The final details of the study are currently being finalized for a start in January 2026.
Publication of the regulatory toxicology Call for Offers
February 18, 2025
A regulatory preclinical toxicology study aimed at assessing the overall effects of HEPHA-440 on the organs will be entrusted to a specialized company certified in Good Laboratory Practices (GLP). This study will be conducted in rabbits, whose sensitivity to LPS is similar to that of humans. It will include two phases:
- A dose-escalation study
- A detailed analysis of acute and long-term toxicity in both males and females, in accordance with GLP standards.
The design has been approved by the French National Agency for Medicines and Health Products Safety (ANSM). The results of these experiments will be crucial to ensuring safe administration in humans and obtaining approval from health authorities. The call for offers has been published on the French government procurement platform (PLACE) and will remain open for one month.
Annual Scientific Meeting
February 17, 2025
At the media library of the Rockefeller Faculty in Lyon, the first annual scientific day of the SyStInn RHU project was held. This event brought together all the teams involved, representatives of partner institutions, and ANR members in charge of monitoring. The progress made in each work package was presented, along with the upcoming steps. This moment was also an opportunity to discuss the challenges encountered and the future directions of the project.
Scientific publication
January 2025
Thanks to a collaboration with a research team of Kyushu University, new data demonstrating the anticancer efficacy of HEPHA-440 in osteosarcoma have been obtained, along with significant advances in understanding its mechanisms of action. This work was published in the open-access scientific journal BJC Reports.
Signature of the Consortium Agreement
December 3, 2024
A Consortium Agreement has been approved and signed by the four partner institutions of the project (UCBL, HEPHAISTOS-Pharma, HCL and CLB), and submitted to the funding organization, the ANR. This document defines the rules of collaboration and specifies the rights and obligations of each party, particularly regarding intellectual property.
Selection of Curapath for the production of regulatory batches
October 2024
Curapath, a Spanish Contract Development and Manufacturing Organization (CDMO) specialized in biological and chemical processes, with strong expertise in liposomal formulations, has been selected for the large-scale production of regulatory batches.
Kick-off Meeting
April 24, 2024
The scientific teams, representatives from partner institutions, and ANR members responsible for monitoring the SyStInn RHU gathered to review the project’s objectives and agree on the provisional timeline for the next five years.
